SELLAS reports FY2024 net loss $30.9M; Phase 3 REGAL trial interim analysis positive

SELLAS Life Sciences Group, Inc.

Net loss $30.9M ($0.50/share) vs $37.3M ($1.34) in FY2023; R&D expenses down to $19.1M.
Cash $13.9M at Dec 31, 2024; raised $25M in January 2025 registered direct offering.
Positive interim analysis for Phase 3 REGAL trial (GPS in AML); final analysis expected upon 80 events in 2025.
Phase 2 SLS009 in r/r AML: 56% ORR in AML-MRC cohorts; median OS >7.7 months vs historic ~2.5 months.
Received multiple regulatory designations: three FDA RPDD, one Fast Track, two EMA ODD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.